Navigation Links
Gerresheimer Further Increases its Sales and Earnings Power
Date:7/15/2008

Sales in the Second Quarter up by 12.8% to EUR276.3m (First Half: up by

15.2% to EUR515.4m)

Adjusted Group Results in the Second Quarter Tripled From EUR6.3m to

EUR17.6m

CEO Dr. Axel Herberg Confirms the Prospects for 2008

DUSSELDORF, Germany, July 15 /PRNewswire-FirstCall/ -- Gerresheimer AG again increased its sales and results in the second quarter of 2008. Compared with the second quarter of 2007, sales improved by 12.8%, or 16.5% on a like-for-like exchange-rate basis, to EUR276.3m. Operating results (Adjusted EBITDA) rose by 20.2% to EUR53.6m (second quarter of 2007: EUR44.6m). In the second quarter of 2008 Gerresheimer therefore achieved an adjusted EBITDA margin of 19.4% (second quarter of 2007: 18.2%). Contributions to this gratifying development were made by the positive sales trend in the market segments of pharmaceutics and cosmetics and by the latest acquisitions. Overall, Gerresheimer therefore continued the improvement in its earnings position in the second quarter and thus the first half of 2008 as a whole. Adjusted Group results increased in the second quarter of 2008 to EUR17.6m and in the first half to EUR27.5m. This means a three-fold rise and means adjusted earnings per share of EUR0.53 in the second quarter and EUR0.82 for the first half of 2008.

"Following our record year in 2007 we have again increased our sales and profit in the first half of 2008," says Dr. Axel Herberg, CEO of Gerresheimer AG. "We expect further growth in all divisions during the course of the year and will consistently continue to focus on pharma & life science."

Just recently, Gerresheimer's discontinuation of peripheral operations such as consumer health care confirmed this concentration on pharmaceutics and life science.

Thanks to the positive development in the second quarter a marked improvement in results has also been achieved for the first half of
'/>"/>

SOURCE Gerresheimer AG
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Yves Lionel Assant is New Chairman of Gerresheimers Supervisory Board
2. 2007 Another Record Year in Terms of Sales and Earnings for Gerresheimer
3. Gerresheimer: Record Year in 2007 and Positive Outlook for 2008
4. Moodys Raises Rating for Gerresheimer
5. Gerresheimer Discontinues Marginal Operations
6. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
7. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
8. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
9. Monitorforhire.com Adds Mobile Phone Capability Further Speeding Access to Experienced Monitors
10. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
11. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... (PRWEB) May 24, 2013 The Oklahoma ... And following its ravage, the mayor of Moore, one of ... new houses, said a report from cnn.com. Reaching out to ... victims complimentary Molderizer and Safe Shield to counter the looming ... report published on May 22, 2013, caused 24 deaths, My ...
(Date:5/23/2013)... Arbor, Mich. Every day, their baby stopped breathing, ... to his lungs. April and Bryan Gionfriddo watched helplessly, ... , "Quite a few doctors said he had a ... April Gionfriddo, about her now 20-month-old son, Kaiba. "At ... we would take it and run with it." , ...
(Date:5/23/2013)... Graphite Metallizing Corporation announces a ... in stainless steel pillow blocks. This series combines ... the application and installation versatility of pillow blocks. ... work exceptionally well when submerged in water, water-soluble ... as acids, alkalies, hydrocarbons, black liquor, and liquid ...
(Date:5/23/2013)... 2013 The maker community is a ... inventions. They focus on learning practical skills while applying ... toward bringing their ideas to life via crowdfunding. A ... on making projects using biology. Glowing Plant has worked ... make them glow with bioluminescence genes, and has now ...
Breaking Biology Technology:Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2
... 10 /PRNewswire-FirstCall/ - Mr. Pierre,Fitzgibbon, President and Chief ... "Company", TSX: ATB) today announced changes to the,management ... by Mr.,Richard Bordeleau, President of the Health & ... pursue news challenges. However, Mr. Bordeleau,will continue to ...
... Audio Webcast Tuesday, September 11, 2007, SAN DIEGO, ... announced today that Neurocrine Biosciences will,present at the Bear ... 11, 2007 at 10:30 a.m. Eastern Time (ET),/7:30 a.m. ... may be accessed on the Company,s website at, http://www.neurocrine.com ...
... the Treatment of Opioid ... ... (Nasdaq: NKTR ) presented results today at the American ... 1 trial of NKTR-118 (oral PEG-naloxol). NKTR-118 is Nektar,s,proprietary investigational ...
Cached Biology Technology:Atrium Innovations Announces Management Changes 2Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting 2Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting 3Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting 4Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting 5
(Date:5/23/2013)... Neuron , the team reveal the interplay of ... funded by the Wellcome Trust and BBSRC. , ... we improve our perceptual abilities. While these changes can ... also affect the fidelity of that response. ... explains: "When you communicate with others, you can make ...
(Date:5/22/2013)... Screening Trial (NLST) investigators also conclude that the ... low-dose computed tomography (LDCT) versus chest X-ray (CXR) ... is achievable at experienced screening centers in the ... to share with their patients about the benefits ... today,s publication in the New England Journal ...
(Date:5/22/2013)... engineers must join together in a major new effort ... crisis in providing Earth,s people with clean water that ... of a comment article in the current edition of ... of the American Chemical Society (ACS), the world,s largest ... Sedlak, Ph.D., and Jerald L. Schnoor, Ph.D., explain that ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... and accurately distinguish species based on a simple DNA ... in the war against a major global disease. ... Biodiversity Foundation, is pioneering the use of DNA "barcodes" ... spread lymphatic filariasis (LF), commonly known as elephantiasis. Using ...
... some kinds of memories for a lifetime. But when ... gray matter also creates temporary memories that help us ... memories exist. For decades, scientists have held that such ... imprecise over the course of several seconds. Now ...
... a practiced eye and Google Earth all played ... fossils that may shed light on the origins ... story, featuring University of Michigan paleontologists Philip Gingerich, ... of a segment on the award-winning television series ...
Cached Biology News:DNA barcoding of mosquito species deployed in bid to end elephantiasis 2DNA barcoding of mosquito species deployed in bid to end elephantiasis 3DNA barcoding of mosquito species deployed in bid to end elephantiasis 4Some short-term memories die suddenly, no fading 2Google Earth aids discovery of early African mammal fossils 2Google Earth aids discovery of early African mammal fossils 3
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Mouse monoclonal antibody raised against a full length recombinant LDB3. NCBI Entrez Gene ID = LDB3...
Mouse polyclonal antibody raised against a partial recombinant NCLN. NCBI Entrez Gene ID = 56926...
Biology Products: